Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Cost-effectiveness of clozapine. A UK clinic-based study.

Aitchison KJ, Kerwin RW.

Br J Psychiatry. 1997 Aug;171:125-30.

PMID:
9337946
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

[Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].

Geronimi-Ferret D, Lesay M, Barges-Bertocchio MH, Cornet-Bonnefont M, Robert H.

Encephale. 1997 Sep;23 Spec No 4:24-31. French.

PMID:
9417402
5.

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D.

Arch Gen Psychiatry. 1999 Jun;56(6):565-72.

PMID:
10359474
6.

[Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].

Bret P, Jolivel C, Bret MC, Veylit S, Martin C, Garcia P.

Encephale. 1998 Jul-Aug;24(4):365-77. French.

PMID:
9809242
7.

The pharmacoeconomics of clozapine: a review.

Meltzer HY, Cola PA.

J Clin Psychiatry. 1994 Sep;55 Suppl B:161-5. Review.

PMID:
7961564
8.

Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

Essock SM, Frisman LK, Covell NH, Hargreaves WA.

Arch Gen Psychiatry. 2000 Oct;57(10):987-94.

PMID:
11015817
9.

The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study.

Hayhurst KP, Brown P, Lewis SW.

J Psychopharmacol. 2002 Jun;16(2):169-75.

PMID:
12095076
11.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
13.

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.

Taylor DM, Wright T, Libretto SE; Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.

J Clin Psychiatry. 2003 May;64(5):589-97.

PMID:
12755664
14.

Clozapine for refractory schizophrenia: the Illinois experience.

Buckman RW, Malan RD.

J Clin Psychiatry. 1999;60 Suppl 1:18-22; discussion 28-30.

PMID:
10037166
15.

Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.

Duggan A, Warner J, Knapp M, Kerwin R.

Br J Psychiatry. 2003 Jun;182:505-8.

16.

New vs. old antipsychotics: the Texas experience.

Reid WH.

J Clin Psychiatry. 1999;60 Suppl 1:23-5; discussion 28-30.

PMID:
10037167
17.
18.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
19.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
20.

Assessing cost-effectiveness of drug interventions for schizophrenia.

Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):44-54.

PMID:
15660705
Items per page

Supplemental Content

Write to the Help Desk